Gastrointestinal Cancer Precision Panel
- Gastrointestinal cancer comprises tumours that arise from any part of the gastrointestinal system (esophagus, stomach, duodenum, pancreas, biliary tract, small and large intestines). Hereditary gastrointestinal cancer syndromes due to specific germline variants are characterized by an increased risk of gastrointestinal tract malignancies, extra-gastrointestinal tract cancers, and benign abnormalities. The currently most well-characterized gastrointestinal cancer susceptibility syndromes are: Lynch syndrome, familial adenomatous polyposis, attenuated familial adenomatous polyposis, MUTYH-associated polyposis, Peutz–Jeghers syndrome, juvenile polyposis syndrome, Cowden syndrome, serrated (hyperplastic) polyposis syndrome, hereditary pancreatic cancer, and hereditary gastric cancer. Timely identification of the causative genes help to predict future cancer risks in carriers of germline pathogenic variants and their family members, enabling individualised surveillance recommendations and highly effective risk-reducing measures that ultimately prevent cancer.
- As many of the oncologists are used to group and study the different cancer types in systems or specialities, the main objective of this product is to provide them with a more manageable diagnostic tool according to their field of knowledge.
The Igenomix Grastrointestinal Cancer Precision Panel is indicated in those cases in which the physician is suspecting of a hereditary cancer syndrome. It is designed to diagnose adults with a personal or family history suggestive of inherited cancer in an organ of the gastrointestinal system, providing important information that may impact cancer treatment as well as cancer risk assessment and management.
- Identify pathogenic cancer susceptibility variants
- Maximize surveillance and preventive strategies for at risk individuals
- Provide options and strategies for targeted treatment, therapeutic planning, and clinical trials
- Perform risk assessment and genetic counselling for family members (cascade testing)
Wang, D. K., Zuo, Q., He, Q. Y., & Li, B. (2021). Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. Frontiers in immunology, 12, 705999. https://doi.org/10.3389/fimmu.2021.705999
Hereditary Gastrointestinal Cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Published in 2019 – Ann Oncol (2019); 00: 1–34
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology: February 2015 – Volume 110 – Issue 2 – p 223-262 doi: 10.1038/ajg.2014.435
Hereditary Gastrointestinal Cancer Syndromes: Role of Imaging in Screening, Diagnosis, and Management. https://doi.org/10.1148/rg.2019180185